WO2013158818A3 - Vaccines and methods to treat lyme disease in dogs - Google Patents

Vaccines and methods to treat lyme disease in dogs Download PDF

Info

Publication number
WO2013158818A3
WO2013158818A3 PCT/US2013/037063 US2013037063W WO2013158818A3 WO 2013158818 A3 WO2013158818 A3 WO 2013158818A3 US 2013037063 W US2013037063 W US 2013037063W WO 2013158818 A3 WO2013158818 A3 WO 2013158818A3
Authority
WO
WIPO (PCT)
Prior art keywords
dogs
vaccines
lyme disease
methods
immunogenic composition
Prior art date
Application number
PCT/US2013/037063
Other languages
French (fr)
Other versions
WO2013158818A2 (en
Inventor
Robert M. LOHSE
Patrick F. M. MEEUS
Jason J. MILLERSHIP
Zach XU
Original Assignee
Zoetis Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Llc filed Critical Zoetis Llc
Priority to EA201491668A priority Critical patent/EA201491668A1/en
Priority to BR112014025740A priority patent/BR112014025740A2/en
Priority to EP13719257.1A priority patent/EP2838555A2/en
Priority to CA2870179A priority patent/CA2870179C/en
Priority to JP2015507162A priority patent/JP2015514776A/en
Priority to AU2013249229A priority patent/AU2013249229A1/en
Priority to CN201380030342.1A priority patent/CN104379164A/en
Publication of WO2013158818A2 publication Critical patent/WO2013158818A2/en
Publication of WO2013158818A3 publication Critical patent/WO2013158818A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The instant invention provides an immunogenic composition comprising an antigenic fragment of OspA protein of Borrelia burgdorferi and a chimeric protein containing antigenic fragments of different phylotypes of OspC protein of Borrelia burgdorferi. Vaccines incorporating the immunogenic composition of the invention, as well as methods of preventing Lyme disease in dogs and/or protecting dogs from Lyme disease using the vaccines are also provided.
PCT/US2013/037063 2012-04-18 2013-04-18 Vaccines and methods to treat lyme disease in dogs WO2013158818A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EA201491668A EA201491668A1 (en) 2012-04-18 2013-04-18 VACCINES AND METHODS FOR THE TREATMENT OF LIME IN DOGS
BR112014025740A BR112014025740A2 (en) 2012-04-18 2013-04-18 Vaccines and Methods to Treat Lyme Disease in Dogs
EP13719257.1A EP2838555A2 (en) 2012-04-18 2013-04-18 Vaccines and methods to treat lyme disease in dogs
CA2870179A CA2870179C (en) 2012-04-18 2013-04-18 Vaccines and methods to treat lyme disease in dogs
JP2015507162A JP2015514776A (en) 2012-04-18 2013-04-18 Vaccines and methods for treating Lyme disease in dogs
AU2013249229A AU2013249229A1 (en) 2012-04-18 2013-04-18 Vaccines and methods to treat Lyme disease in dogs
CN201380030342.1A CN104379164A (en) 2012-04-18 2013-04-18 Vaccines and methods to treat lyme disease in dogs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261635031P 2012-04-18 2012-04-18
US61/635,031 2012-04-18

Publications (2)

Publication Number Publication Date
WO2013158818A2 WO2013158818A2 (en) 2013-10-24
WO2013158818A3 true WO2013158818A3 (en) 2014-04-17

Family

ID=48193279

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/037063 WO2013158818A2 (en) 2012-04-18 2013-04-18 Vaccines and methods to treat lyme disease in dogs

Country Status (10)

Country Link
EP (1) EP2838555A2 (en)
JP (1) JP2015514776A (en)
CN (1) CN104379164A (en)
AR (1) AR090726A1 (en)
AU (1) AU2013249229A1 (en)
BR (1) BR112014025740A2 (en)
CA (1) CA2870179C (en)
EA (1) EA201491668A1 (en)
UY (1) UY34745A (en)
WO (1) WO2013158818A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10086057B2 (en) 2014-10-08 2018-10-02 Virginia Commonwealth University Stage specific diagnostic antigens, assay and vaccine for lyme disease
AU2018379121B2 (en) 2017-12-04 2024-05-02 Intervet International B.V. Canine lyme disease vaccine
CN110483624B (en) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 Borrelia garinii OspA protein C-terminal peptide segment and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004175A1 (en) * 1991-08-15 1993-03-04 Smithkline Beecham Biologicals (S.A.) Osp a proteins of borrelia burgdorferi subgroups, encoding genes and vaccines
WO2009135118A2 (en) * 2008-05-02 2009-11-05 Virginia Commonwealth University Lyme disease vaccine
WO2010132758A2 (en) * 2009-05-14 2010-11-18 Gomes-Solecki Maria J Ospc-based diagnostic test for lyme disease
WO2012054580A2 (en) * 2010-10-20 2012-04-26 Virginia Commonwealth University Polyvalent chimeric ospc vaccinogen and diagnostic antigen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567042A (en) 1983-06-15 1986-01-28 American Home Products Corporation Inactivated canine coronavirus vaccine
US4567043A (en) 1983-06-15 1986-01-28 American Home Products Corporation (Del.) Canine corona virus vaccine
US6872550B1 (en) 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
AU5328299A (en) 1998-07-31 2000-02-21 Gundersen Lutheran Medical Foundation, Inc. Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004175A1 (en) * 1991-08-15 1993-03-04 Smithkline Beecham Biologicals (S.A.) Osp a proteins of borrelia burgdorferi subgroups, encoding genes and vaccines
WO2009135118A2 (en) * 2008-05-02 2009-11-05 Virginia Commonwealth University Lyme disease vaccine
WO2010132758A2 (en) * 2009-05-14 2010-11-18 Gomes-Solecki Maria J Ospc-based diagnostic test for lyme disease
WO2012054580A2 (en) * 2010-10-20 2012-04-26 Virginia Commonwealth University Polyvalent chimeric ospc vaccinogen and diagnostic antigen

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
C. G. EARNHART ET AL: "OspC Phylogenetic Analyses Support the Feasibility of a Broadly Protective Polyvalent Chimeric Lyme Disease Vaccine", CLINICAL AND VACCINE IMMUNOLOGY, vol. 14, no. 5, 14 March 2007 (2007-03-14), pages 628 - 634, XP055100820, ISSN: 1556-6811, DOI: 10.1128/CVI.00409-06 *
CHRISTOPHER G. EARNHART ET AL: "An Octavalent Lyme Disease Vaccine Induces Antibodies That Recognize All Incorporated ospC Type-Specific Sequences", HUMAN VACCINES, 1 November 2007 (2007-11-01), pages 281 - 289, XP055100831, Retrieved from the Internet <URL:http://www.landesbioscience.com/journals/vaccines/article/4661/> *
D.V.L. RHODES ET AL: "Identification of Borrelia burgdorferi ospC genotypes in canine tissue following tick infestation: Implications for Lyme disease vaccine and diagnostic assay design", THE VETERINARY JOURNAL, vol. 198, no. 2, 17 August 2013 (2013-08-17), pages 412 - 418, XP055100470, ISSN: 1090-0233, DOI: 10.1016/j.tvjl.2013.07.019 *
IVANOVA L ET AL: "Comprehensive seroprofiling of sixteen B. burgdorferi OspC: Implications for Lyme disease diagnostics design", CLINICAL IMMUNOLOGY, ACADEMIC PRESS, US, vol. 132, no. 3, 1 September 2009 (2009-09-01), pages 393 - 400, XP026393908, ISSN: 1521-6616, [retrieved on 20090702] *

Also Published As

Publication number Publication date
AU2013249229A1 (en) 2014-10-23
EP2838555A2 (en) 2015-02-25
WO2013158818A2 (en) 2013-10-24
CA2870179C (en) 2018-09-04
CA2870179A1 (en) 2013-10-24
AR090726A1 (en) 2014-12-03
UY34745A (en) 2013-11-29
EA201491668A1 (en) 2015-08-31
CN104379164A (en) 2015-02-25
BR112014025740A2 (en) 2017-07-04
JP2015514776A (en) 2015-05-21

Similar Documents

Publication Publication Date Title
IL267997A (en) Compositions, formulations and methods for treating ocular diseases
MX340739B (en) Ospa chimeras and use thereof in vaccines.
PH12014502406A1 (en) Anti-il-23p19 antibodies
PH12014501108A1 (en) Anti-il-36r antibodies
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
MX2019003004A (en) Compositions for immunising against staphylococcus aerus.
ZA201200832B (en) Immunogenic composition comprising antigenic s. aureus proteins
MX2013011939A (en) Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a.
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
BR112015004327A2 (en) biodegradable compositions, methods and uses thereof
WO2011122869A3 (en) Cosmetic composition comprising coumestrol or a bean extract containing coumestrol for skin care
EP2596017A4 (en) Cross-protective pathogen protection, methods and compositions thereof
WO2014133744A3 (en) Oral care compositions
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
WO2014018274A8 (en) Compositions comprising chimeric ospa molecules and methods of use thereof
WO2013158818A3 (en) Vaccines and methods to treat lyme disease in dogs
WO2012103444A3 (en) Immunogenic compositions and reagents for preparing
WO2012116992A3 (en) Oral use of a composition comprising steviol or isosteviol
WO2014133746A3 (en) Oral care compositions
WO2014005942A3 (en) Essential oil of sweet marjoram, composition comprising it, cosmetic treatment method and use
WO2015022470A3 (en) Lyme disease vaccines
TN2014000207A1 (en) Anti il-36r antibodies
WO2012003205A3 (en) Vaccine against ehrlichia canis
MX346860B (en) Compositions and methods for vaccinating cattle.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13719257

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2870179

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 201491668

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2015507162

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2013249229

Country of ref document: AU

Date of ref document: 20130418

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2013719257

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013719257

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014025740

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/000642

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 112014025740

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20141015